Zhu et al. (2019) found that Myd88 signaling plays a key role in pancreatic cancer-induced inflammation, thereby triggering the development of cachexia. It has been shown that aberrant activation of these signaling pathways is closely associated with DLBCL pathogenesis, malignant proliferation, invasion, metastasis, drug resistance and poor prognosis. Some scholars have found that there is a higher frequency of Myd88 mutations in DLBCL, which is the main reason for triggering abnormal activity of the nuclear factor kappa B (NF-κB) pathway (Yu et al., 2018). The gene discussed is MYD88; the disease is familial pancreatic carcinoma.